INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY

被引：0

作者：

DeAngelo, D. J. ^{[1
]}

Jabbour, E. J. ^{[2
]}

Stelljes, M. ^{[3
]}

Liedtke, M. ^{[4
]}

Stock, W. ^{[5
]}

Goekbuget, N. ^{[6
]}

Martinelli, G. ^{[7
]}

O'Brien, S. ^{[8
]}

Wang, K. ^{[9
]}

Wang, T. ^{[10
]}

Paccagnella, M. L. ^{[10
]}

Sleight, B. ^{[10
]}

Vandendries, E. ^{[11
]}

Advani, A. S. ^{[12
]}

Kantarjian, H. M. ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Klinikum mUNSTER, Munster, Germany

[4] Stanford Canc Ctr, Stanford, CA USA

[5] Univ Chicago Med, Chicago, IL USA

[6] Univ Hosp Frankfurt, Frankfurt, Germany

[7] Univ Bologna, Bologna, Italy

[8] Univ Calif Irvine, Orange, CA 92668 USA

[9] Pfizer Inc, Pearl River, NY USA

[10] Pfizer Inc, Groton, CT 06340 USA

[11] Pfizer Inc, Cambridge, MA USA

[12] Cleveland Clin Main Campus, Cleveland, OH USA

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S499

引用

页码：184 / 184

页数：1

共 50 条

[1] Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy
Stelljes, M.
Kreuzer, K. -A
Deangelo, D. J.
Advani, A. S.
Goekbuget, N.
Liedtke, M.
Stock, W.
Martinelli, G.
O'Brien, S.
Wang, K.
Wang, T.
Paccagnella, M. L.
Sleight, B.
Vandendries, E.
Jabbour, E. J.
Kantarjian, H. M.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 201 - 202
[2] EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN OLDER PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ENROLLED IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL
Jabbour, E. J.
Advani, A. S.
Stelljes, M.
Stock, W.
Liedtke, M.
Goekbuget, N.
Martinelli, G.
O'Brien, S.
Wang, K.
Wang, T.
Paccagnella, M. L.
Sleight, B.
Vandendries, E.
DeAngelo, D. J.
Kantarjian, H. M.
HAEMATOLOGICA, 2016, 101 : 32 - 32
[3] Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.
DeAngelo, Daniel J.
Jabbour, Elias
Stelljes, Matthias
Liedtke, Michaela
Stock, Wendy
Gokbuget, Nicola
Martinelli, Giovanni
O'Brien, Susan Mary
Wang, Kongming
Wang, Tao
Paccagnella, M. Luisa
Sleight, Barbara
Vandendries, Erik
Advani, Anjali S.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status
Advani, Anjali S.
Jabbour, Elias J.
Stelljes, Matthias
Stock, Wendy
Liedtke, Michaela
Goekbuget, Nicola
O'Brien, Susan M.
White, Jane Liang
Wang, Tao
Laird, A. Douglas
Vandendries, Erik
Kantarjian, Hagop M.
BLOOD, 2017, 130
[5] Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level
Kantarjian, Hagop M.
Stock, Wendy
Cassaday, Ryan D.
DeAngelo, Daniel J.
Jabbour, Elias J.
O'Brien, Susan M.
Stelljes, Matthias
Wang, Tao
Paccagnella, Luisa
Nguyen, Kevin
Sleight, Barbara
Vandendries, Erik
Laird, A. Douglas
Advani, Anjali S.
BLOOD, 2017, 130
[6] Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.
Cassaday, Ryan Daniel
DeAngelo, Daniel J.
Martinelli, Giovanni
Stock, Wendy
Stelljes, Matthias
Gokbuget, Nicola
Advani, Anjali S.
O'Brien, Susan Mary
Liedtke, Michaela
Merchantx, Akil Abid
Wang, Tao
Vandendries, Erik
Marks, David I.
Jabbour, Elias
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Jabbour, Elias J.
DeAngelo, Daniel J.
Stelljes, Matthias
Stock, Wendy
Liedtke, Michaela
Gokbuget, Nicola
O'Brien, Susan
Wang, Tao
Paccagnella, M. Luisa
Sleight, Barbara
Vandendries, Erik
Advani, Anjali S.
Kantarjian, Hagop M.
CANCER, 2018, 124 (08) : 1722 - 1732
[8] Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.
Jabbour, Elias
Advani, Anjali S.
Stelljes, Matthias
Stock, Wendy
Liedtke, Michaela
Gokbuget, Nicola
Martinelli, Giovanni
O'Brien, Susan Mary
Wang, Kongming
Wang, Tao
Paccagnella, M. Luisa
Sleight, Barbara
Vandendries, Erik
DeAngelo, Daniel J.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase
Advani, Anjali S.
Jabbour, Elias J.
Stelljes, Matthias
DeAngelo, Daniel J.
Liedtke, Michaela
Stock, Wendy
Gokbuget, Nicola
O'Brien, Susan
Wang, Kongming
Wang, Tao
Paccagnella, M. Luisa
Sleight, Barbara
Vandendries, Erik
Kantarjian, Hagop M.
BLOOD, 2016, 128 (22)
[10] Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial
Stelljes, Matthias
Advani, Anjali S.
DeAngelo, Daniel J.
Wang, Tao
Neuhof, Alexander
Vandendries, Erik
Kantarjian, Hagop
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09): : E836 - E843

← 1 2 3 4 5 →